|
시장보고서
상품코드
2078389
유전자 침묵 시장 규모, 점유율 및 성장 분석 : 기술별, 전달 시스템별, 용도별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Gene Silencing Market Size, Share, and Growth Analysis, By Technology (siRNA, miRNA ), By Delivery System (Lipid Nanoparticles, GalNAc Conjugates), By Application, By End-User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 유전자 침묵 시장 규모는 2024년에 35억 2,000만 달러로 평가되었고, 2025년 40억 6,000만 달러에서 2033년까지 128억 5,000만 달러로 성장하여 예측 기간(2026-2033년)에 CAGR 15.32%를 기록할 전망입니다.
세계 유전자 침묵 시장은 RNA 간섭, 안티센스 올리고뉴클레오티드, CRISPR 기반 후성유전학적 편집기 등 첨단 기술이 특징이며, 이들 모두는 치료 및 농업 분야에서 표적 유전자의 발현을 억제하도록 설계되었습니다. 이 시장은 DNA를 변형하지 않고도 질병 관련 단백질을 안전하게 조절할 수 있는 능력 덕분에 활기를 띠고 있으며, 기존의 유전자 치료를 대체할 매력적인 대안이 되고 있습니다. 시장의 급속한 성장은 만성 질환 발병률 증가와 정밀 의학에 대한 수요 증가에 힘입어 이루어지고 있으며, 상업적 투자를 촉진하는 규제 당국의 승인으로 인해 더욱 가속화되고 있습니다. 또한, AI를 활용한 자동화는 표적 특정 및 올리고뉴클레오티드 설계와 같은 과정을 효율화함으로써 이러한 확대에 크게 기여하고 있습니다. 이로 인해 개발 파이프라인이 가속화되고, 투자자들의 신뢰가 높아지며, 다양한 분야의 제휴와 혁신이 촉진되고 있습니다.
세계 유전자 침묵 시장의 성장 요인
세계 유전자 침묵 시장은 지질 나노입자 및 접합체 시스템과 같은 혁신적인 전달 플랫폼의 발전에 힘입어 크게 성장하고 있습니다. 이들은 침묵화제의 세포 내 흡수 및 안정성을 크게 향상시킵니다. 이러한 기술은 분해 위험을 최소화하고 표적 특이성을 높임으로써 개발자와 투자자 모두에게 신뢰감을 주고 있습니다. 그 결과, 연구 활동이 급속도로 확대되고 공동 연구도 늘어나면서, 보다 광범위한 파이프라인 개발을 촉진하고 시장 진입을 용이하게 하고 있습니다. 또한, 이러한 치료법의 안전성 프로파일이 개선됨에 따라 규제 당국의 승인을 얻기가 더 쉬워졌으며, 이는 유전자 침묵 분야의 성장을 더욱 촉진하는 동시에 새로운 벤처 캐피털 투자와 전략적 제휴를 유치하고 있습니다.
세계 유전자 침묵 시장의 제약 요인
세계 유전자 침묵 시장은 혁신적인 치료법과 관련된 규제상의 불확실성으로 인해 큰 제약을 받고 있습니다. 이러한 모호함은 승인까지의 기간이 길어지거나 규정 준수 요건이 강화되는 결과로 이어져, 투자를 주저하게 하고 시장 진입을 지연시킬 가능성이 있습니다. 제품 분류, 안전성 평가 기준 및 장기적 영향 평가에 대한 명확성이 부족하기 때문에 광범위한 전임상 및 임상 데이터 수집이 필요합니다. 그 결과, 개발 기업은 규제 체계에 대응하고 위험을 완화하기 위해 추가 자원을 투입해야 하며, 이로 인해 개발 비용이 증가하고 프로젝트의 매력이 떨어지게 됩니다. 이러한 불확실성은 신제품 출시를 지연시킬 뿐만 아니라, 생명공학 기업간의 제휴에 관한 의사결정에도 영향을 미쳐 시장 성장을 더욱 저해하고 있습니다.
세계 유전자 침묵 시장 동향
세계 유전자 침묵 시장은 정밀 RNA 치료제의 급속한 발전에 힘입어 큰 변화를 겪고 있습니다. 각 제약사가 siRNA나 안티센스 올리고뉴클레오티드 등의 유전자 침묵 기술을 개발 파이프라인에 점점 더 많이 도입함에 따라, 특정 질환 경로를 표적으로 하는 맞춤형 솔루션에 명확한 초점이 맞추어지고 있습니다. 이러한 경향은 선택성을 높이고 오프타겟 효과를 최소화하며, 이는 환자의 안전에 있어 매우 중요합니다. 생명공학 기업과 대형 제약사의 공동 사업이 중개연구(translational research)를 주도하고 있는 한편, 환자 지원 단체들의 지지가 높아짐에 따라 혁신적인 치료법에 대한 수요도 증가하고 있습니다. 그 결과, 유전자 침묵 기술은 끊임없이 진화하는 차세대 치료제 분야에서 필수적인 요소로 자리 잡고 있습니다.
자주 묻는 질문
목차
서론
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 유전자 침묵 시장 규모 : 기술별
세계의 유전자 침묵 시장 규모 : 딜리버리 시스템별
세계의 유전자 침묵 시장 규모 : 용도별
세계의 유전자 침묵 시장 규모 : 최종사용자별
세계의 유전자 침묵 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
LSH 26.07.08Global Gene Silencing Market size was valued at USD 3.52 Billion in 2024 and is poised to grow from USD 4.06 Billion in 2025 to USD 12.85 Billion by 2033, growing at a CAGR of 15.32% during the forecast period (2026-2033).
The global gene silencing market features advanced technologies such as RNA interference, antisense oligonucleotides, and CRISPR-based epigenetic editors, all designed to inhibit target gene expression for therapeutic and agricultural applications. This market thrives on the capability to modulate disease-related proteins safely without altering DNA, presenting a compelling alternative to traditional gene therapies. The rapid escalation in market growth is propelled by the rising incidences of chronic diseases and the increasing demand for precision medicine, enhanced by regulatory approvals that facilitate commercial investment. Furthermore, AI-driven automation significantly contributes to this expansion by streamlining processes such as target identification and oligonucleotide design, thereby expediting the development pipeline and boosting investor confidence, which stimulates partnerships and innovations across various sectors.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gene Silencing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Gene Silencing Market Segments Analysis
Global gene silencing market is segmented by technology, delivery system, application, end-user and region. Based on technology, the market is segmented into siRNA (Small Interfering RNA), miRNA (MicroRNA), Antisense Oligonucleotides (ASO) and shRNA. Based on delivery system, the market is segmented into Lipid Nanoparticles (LNP) and GalNAc Conjugates. Based on application, the market is segmented into Cardiovascular, Neurological and Oncology. Based on end-user, the market is segmented into Pharma & Biotech, Research Institutes and CDMOs. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Gene Silencing Market
The Global Gene Silencing market is significantly driven by the advancement of innovative delivery platforms, such as lipid nanoparticles and conjugate systems, which greatly improve the cellular uptake and stability of silencing agents. These technologies minimize the risk of degradation and enhance target specificity, instilling confidence in developers and investors alike. Consequently, this leads to a rapid acceleration of research initiatives and an uptick in collaborations, promoting a more extensive pipeline development and facilitating market entry. Additionally, the enhanced safety profile of these therapies supports regulatory acceptance, further propelling growth in the gene silencing sector and attracting new venture capital investments and strategic partnerships.
Restraints in the Global Gene Silencing Market
The Global Gene Silencing market faces significant restraints due to regulatory uncertainties associated with innovative therapies. These ambiguities result in extended approval timelines and increased compliance demands, which can dissuade investment and slow down market entry. The lack of clarity regarding product classification, criteria for safety assessments, and evaluations of long-term effects necessitates extensive preclinical and clinical data collection. As a result, developers must divert additional resources towards navigating regulatory frameworks and mitigating risks, thereby inflating development costs and diminishing the appeal of projects. This uncertainty not only delays the introduction of new products but also impacts collaborative decisions among biotechnology companies, further hindering market growth.
Market Trends of the Global Gene Silencing Market
The Global Gene Silencing market is experiencing significant transformation, driven by rapid advancements in precision RNA therapeutics. With pharmaceutical companies increasingly incorporating gene silencing technologies, such as siRNA and antisense oligonucleotides, into their development pipelines, there is a clear focus on tailored solutions that target specific disease pathways. This trend is enhancing selectivity and minimizing off-target effects, which is crucial for patient safety. Collaborative ventures between biotech firms and major pharmaceutical players are propelling translational research efforts, while growing support from patient advocacy groups elevates the demand for innovative treatments. Consequently, gene silencing technologies are becoming integral to the evolving landscape of next-generation therapeutics.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Gene Silencing Market Size by Technology & CAGR (2026-2033)
- Market Overview
- siRNA (Small Interfering RNA)
- miRNA (MicroRNA)
- Antisense Oligonucleotides (ASO)
- shRNA
Global Gene Silencing Market Size by Delivery System & CAGR (2026-2033)
- Market Overview
- Lipid Nanoparticles (LNP)
- GalNAc Conjugates
Global Gene Silencing Market Size by Application & CAGR (2026-2033)
- Market Overview
- Cardiovascular
- Neurological
- Oncology
Global Gene Silencing Market Size by End-User & CAGR (2026-2033)
- Market Overview
- Pharma & Biotech
- Research Institutes
- CDMOs
Global Gene Silencing Market Size & CAGR (2026-2033)
- North America (Technology, Delivery System, Application, End-User)
- US
- Canada
- Europe (Technology, Delivery System, Application, End-User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Technology, Delivery System, Application, End-User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Technology, Delivery System, Application, End-User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Technology, Delivery System, Application, End-User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Alnylam Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ionis Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Arrowhead Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Silence Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sirnaomics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Arctus Biosciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Wave Life Sciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Translate Bio (Sanofi)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- RNAi Therapeutics (Dicerna - Novo Nordisk)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Benitec Biopharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Arbutus Biopharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sirnaomics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Minas Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Generation Bio
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Entrada Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Precision BioSciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Arctus Biosciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Phio Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- OliX Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sirnaomics Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
